iCardiac Technologies IQ-CSRC study shows potential for faster drug development
The study, which recreated five earlier drug cardiac safety studies, utilized the proprietary Early Precision QT methodology developed by iCardiac Technologies. The results show highly significant improvement in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.